{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T19:39:16Z","timestamp":1770493156112,"version":"3.49.0"},"reference-count":10,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,12,12]]},"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>Cemiplimab is a highly potent, hinge-stabilized human IgG4 monoclonal antibody (mAb) targeting programmed cell death 1 (PD-1) receptor approved for patients with locally advanced or metastatic cutaneous squamous cell carcinoma (SCC) who are not candidates for curative surgery or curative radiation. Recently, the phase 3 trial EMPOWER-Cervical 1 has investigated cemiplimab in patients with recurrent\/metastatic cervical cancer. At interim analysis, overall survival (OS), progression free survival (PFS) and objective response rate (ORR) in overall and SCC populations favored cemiplimab over single agent chemotherapy. Cervical SCCs are the first for incidence among Human Papilloma Virus (HPV) related neoplasms and are highly correlated (about 95%) with the viral infection. Similarly, penile and vulvar SCC may develop on chronic HPV infections or on dermatological chronic conditions (ie, lichen). The molecular and viral similarities between external genital SCC and SCC originating from the cervical epithelium could be the rationale for using cemiplimab to treat locally advanced or metastatic penile and vulvar SCC as well. Some retrospective data have shown that cemiplimab may provide objective response and clinical benefit to some patients with penile or vulvar SCC and is overall safe to utilize in this population. Given the complexity of the immune activation and the considerable variability in tumor biology across patients and tumor types, the identification of biomarkers to warrant patient selection needs to be further explored. Ongoing clinical trials will hopefully shed light on the treatment paradigm of these rare tumors too, with special regard to the ideal combination and sequencing of immunotherapeutic strategies.<\/jats:p>","DOI":"10.1136\/jitc-2021-003540","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T10:06:40Z","timestamp":1643623600000},"page":"e003540","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02721732","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02721732","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Elisabetta","family":"Gambale","sequence":"first","affiliation":[{"name":"Clinical Oncology Unit, University Hospital Careggi, Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Fancelli","sequence":"additional","affiliation":[{"name":"Clinical Oncology Unit, University Hospital Careggi, Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Caliman","sequence":"additional","affiliation":[{"name":"Clinical Oncology Unit, University Hospital Careggi, Firenze, Italy"},{"name":"Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina","family":"Petrella","sequence":"additional","affiliation":[{"name":"Clinical Oncology Unit, University Hospital Careggi, Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Doni","sequence":"additional","affiliation":[{"name":"Clinical Oncology Unit, University Hospital Careggi, Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Pillozzi","sequence":"additional","affiliation":[{"name":"Clinical Oncology Unit, University Hospital Careggi, Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[{"name":"Clinical Oncology Unit, University Hospital Careggi, Firenze, Italy"},{"name":"Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"2025100312364104000_10.1.e003540.1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025100312364104000_10.1.e003540.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00228-2"},{"key":"2025100312364104000_10.1.e003540.3","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1760"},{"key":"2025100312364104000_10.1.e003540.4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejca.2021.08.018","article-title":"Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma","volume":"157","author":"Baggi","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025100312364104000_10.1.e003540.5","article-title":"Profound and durable responses with PD-1 immune checkpoint inhibitors in patients with metastatic penile squamous cell carcinoma","volume":"3","author":"Steck","year":"2021","journal-title":"Curr Probl Cancer"},{"key":"2025100312364104000_10.1.e003540.6","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14744","article-title":"Metastatic penile squamous cell carcinoma successfully treated with cemiplimab in an HIV patient","volume":"34","author":"Proietti","year":"2021","journal-title":"Dermatol Ther"},{"key":"2025100312364104000_10.1.e003540.7","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1159\/000517008","article-title":"Cemiplimab for cisplatin resistant metastatic penile cancer","volume":"14","author":"Denis","year":"2021","journal-title":"Case Rep Oncol"},{"key":"2025100312364104000_10.1.e003540.8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000491090","article-title":"Pembrolizumab in recurrent squamous cell carcinoma of the vulva: case report and review of the literature","volume":"84","author":"Shields","year":"2019","journal-title":"Gynecol Obstet Invest"},{"key":"2025100312364104000_10.1.e003540.9","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2217\/fon-2020-0823","article-title":"Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma","volume":"17","author":"Keeping","year":"2021","journal-title":"Future Oncol"},{"key":"2025100312364104000_10.1.e003540.10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1351"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003540","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:36:51Z","timestamp":1759520211000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,31]]},"published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1136\/jitc-2021-003540"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003540","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}